DR REDDY LAB
More than family business: Drugmakers make costly, long-term strategic shifts as next generation steps into bigger roles
India's family-run pharmaceutical companies are entering a new phase as the next generation takes on larger leadership roles and steers businesses towards complex generics, peptides, biologics, contract manufacturing and advanced therapeutics. Laurus Labs, Granules India, Bharat Biotech, Sun Pharma and Torrent Pharma are investing in capabilities that require greater scientific expertise, significant capital and longer gestation periods. The key question is whether the successors can turn these long-term bets into sustainable growth and create lasting value for investors.
Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return
In 2026, India's pharmaceutical stocks are making headlines with impressive year-to-date gains. This surge is driven by strong domestic demand alongside enhanced profitability from new product launches. Notable players like Laurus Labs and Gland Pharma have recorded remarkable returns, topping 100%. Amid challenges faced by other sectors, the pharmaceutical field demonstrates resilience. Analysts are optimistic but advise exercising caution regarding potential market volatility and the durability of this sector's performance.
Short-term headwinds, yes; owning the ecosystem is better: 20 healthcare stocks with downside risk of 23% to upside potential of 41%
The healthcare sector is under scrutiny. The issue is pricing: What medicines cost and on what hospitals and the rest of the health ecosystem charge. And both the government and the courts have stepped in. At one level, that is not entirely a bad thing. Check out Stock Reports Plus, powered by Refinitiv, for price targets of over 4,000 listed stocks along with detailed company analysis focusing on five key components – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. SR+ Reports is a complimentary offering to ETPrime members.
AI halves drug discovery times, but =trial bottleneck remains a costly reality
Novo Nordisk, Sanofi and Dr Reddy’s Laboratories are among the companies exploring applications ranging from drug discovery to laboratory automation and research.
Two Trades for Today: A top pharma company for a 5.3% upmove, a mid-cap chemical maker’s stock for an almost 7% rise
Our technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical calls for today.
DRL says cap on trade margins a positive, posts 36% dip in Q2 PAT
In the second quarter of FY2027, Dr. Reddy's Labs experienced a downturn in both revenue and profit. However, the company supports new trade margin regulations that aim to improve access to vital medicines. With a commitment to boosting its core business performance, management is also dedicated to exploring growth avenues.
- Go To Page 1
Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruption
Dr Reddy’s Laboratories has expanded its generic semaglutide portfolio with Obeda Pro and Obeda Plus after supplies of its original Obeda injection were halted in July for technical evaluation. The new brands are manufactured by Hetero Labs, while distributors say the company may discontinue Obeda injectable supplies. Dr Reddy’s denies a replacement strategy.
Stocks in news: Swiggy, Infosys, HPCL, eMudhra, Adani Power, Shriram Finance, Tata Motors and NLC India
Indian equity markets faced continued downward pressure, marked by persistent selling and negative global indicators. The Nifty 50 index saw a decline, with analysts pointing out critical resistance and support points. Numerous companies disclosed their financial results, showcasing a mix of profits and setbacks for the September quarter. As various firms prepare to announce their quarterly earnings, market participants should remain vigilant over the coming days.
Market wrap: ITC, Apollo Hospital, Dr Reddy's Labs, Bajaj Auto top gainers and losers on Nifty and Sensex on Monday
Indian equity markets ended lower on Monday as rising bond yields and continued FII outflows weighed on sentiment. The Nifty fell 0.70% to 22,363, while the Sensex lost 0.76% to 71,925. FMCG stocks led sectoral losses, while auto stocks gained. Dr Reddy’s and Bajaj Auto topped Nifty gainers.
FSSAI pulls up Dr Reddy's, Nestle Health Science over Celevida claims
The Food Safety and Standards Authority of India (FSSAI) said the product was advertised as providing high-protein support for preserving lean muscle during GLP-1/GIP therapies, commonly used in weight-loss treatment.
I-T dept moves appellate tribunal against Rs 32.66-cr tax relief to Dr Lal PathLabs
Dr Lal PathLabs, in a regulatory filing, said that it received an intimation on Wednesday regarding an appeal filed by the I-T Department before the Income Tax Appellate Tribunal (ITAT), New Delhi.
Inside 11-quarter high earnings pomp, 46 companies may wipe out up to 84% of their Q2 profits
At least 46 companies are expected to report double-digit profit declines in Q2, despite Motilal Oswal projecting 22% earnings growth for its coverage universe. Autos, cement, healthcare, consumer and cap goods are among sectors facing pressure, highlighting the uneven nature of the September-quarter earnings recovery.
When nothing is cheap, winners may come from any corner: 19 stocks with downside to upside potential of -28% to plus 22%
Because each pharma company took a different road, they no longer rise and fall together. Where any one of them stands in 10 years depends on what it chose in the last five or six. So, one name can do wonderfully while the one sitting next to it does very little. Stock Reports Plus, powered by Refinitiv, is a comprehensive report that evaluates five key components of 4,000+ listed stocks – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. The simple average of the above-mentioned five component ratings is normally distributed to reach an average score.
Nifty 50 companies likely to log strong double-digit growth in Q2
Revenue and net profit of Nifty 50 companies are projected to grow by nearly 20% year-on-year. Analysts note that performance is driven by sectors like automobiles, banking, and oil. Operating margins, however, might contract slightly due to input cost pressures and inflation. Key sectors show varied conditions, balancing strong demand against potential challenges. Overall, medium to long-term outlook remains optimistic, despite some near-term volatility.
Market wrap: Infosys, Dr Reddy's Labs, Tata Motors PV, Power Grid top gainers and losers on Nifty and Sensex on Monday
Indian equity markets ended sharply lower on Monday, with the Nifty falling 1.56% and the Sensex declining 1.52% as all sectoral indices closed in the red. PSU banks and realty stocks led the decline, while Dr Reddy’s Labs and Infosys were among the few gainers. India VIX surged 12.54%.
Takeda partners Dr Reddy's to launch dengue vaccine Qdenga in India from 2027
Takeda and Dr. Reddy's Labs will promote the Qdenga dengue vaccine in India. This pioneering vaccine is expected to launch in the first half of 2027. It will be available for paediatric and adult vaccination in the private market. The vaccine received approval from India's regulatory agency in July 2026. Pricing details for the Indian market have not yet been disclosed.
MFs raise healthcare bets for 4th straight month to 71-month high. Should investors follow?
Mutual funds raised their healthcare allocation for the fourth straight month in August 2026 to 8.4%, the highest in 71 months. Experts attribute the increase to resilient demand, earnings visibility, structural growth and opportunities in hospitals, specialty pharma and healthcare outsourcing. However, they caution investors against chasing the rally and suggest focusing on valuations, earnings quality and long-term prospects.
Dr Reddy's Laboratories Q2 Results: Profit rises 7% YoY to Rs 1,347 crore, revenue up 10%
Dr Reddy's Laboratories Q2 Results: Generic drugmaker Dr Reddy's Labs reported 7% growth in its net profit at Rs 1,347 crore in the September quarter, compared with Rs 1,255 crore in the same quarter of last year. Revenue from operations increased 10% YoY to Rs 8828 crore.
Dr. Reddy's Laboratories Q1 Results: PAT rises 2% YoY to Rs 1,418 crore, revenue jumps 11%
Dr Reddy's Laboratories Q1 Results: Pharma major Dr. Reddy's Laboratories reported a marginal 2% year-on-year (YoY) growth in its consolidated net profit at Rs 1,418 crore for the first quarter ended June. Revenue from operations rose 11% YoY to Rs 8,545 crore.
Dr Reddy's Labs Q4 Results: Cons PAT jumps 22% to Rs 1,594 crore; Rs 8 per share dividend announced
Dr Reddy's Labs Q4 Results: Dr Reddy's Laboratories on Friday reported a consolidated net profit growth of 22% to Rs 1,594 crore in Q4FY25 versus Rs 1,307 crore reported in the year ago period.
Dr Reddy's Labs Q3 Results: Cons PAT rises 2% YoY to Rs 1,413 crore, revenue up 16%
Dr Reddy's Labs Q3 Results: Dr Reddy's Laboratories on Thursday reported a 2% year-on-year growth in its December quarter consolidated net profit at Rs 1,413 crore versus Rs 1,379 crore posted in the year ago period.
Dr Reddy's Labs shares up 3% after Q2 results. What should investors do?
Dr. Reddy's Labs reported a 15% decline in Q2 net profit, despite a 17% rise in revenue driven by global generics. While analysts acknowledge the strong revenue momentum, opinions are divided on the stock's future prospects, with ratings ranging from 'Buy' to 'Sell'.
Dr. Reddy's Lab Q1 Results: Profit down 1% to Rs 1,392 crore but revenue jumps 14%
Dr. Reddy's Lab Q1 Results: While announcing the quarterly numbers, the company's board also approved split of equity shares in the ratio of 1:5, which means that 1 existing share will split into 5. The company said its revenue growth during the quarter was largely driven by growth in global generics revenues in North America as well as India.
Dr. Reddy's Labs announces share buy back, stock jumps 4%
The company said the price represents an 18.6% premium to the average closing price of shares for the two weeks up to February 16, 2016.
Buy Dr Reddy's Lab with a target of Rs 2400: Prakash Gaba
Dr Reddy's Lab is a 'BUY' call with a target of Rs 2400 and a stop loss of Rs 2340-2335.
Buy Dr Reddy's Labs with a target of Rs 2500: Prakash Gaba
Buy Dr Reddy's Labs with a target of Rs 2500 and a stop loss of Rs 2420: Prakash Gaba.
Buy Dr Reddy's Lab with target price of Rs 2350: Shardul Kulkarni
Dr Reddy's Lab Ltd is a 'BUY' call with a target of Rs 2350 and a stop loss of Rs 2180.
Load More
